Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 2:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 1,928 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Consent Clear all
Recruiting Not applicable Interventional

Achieving Chronic Care equiTy by leVeraging the Telehealth Ecosystem

NCT06598436
View directory record Official record
Conditions
Diabetes
Interventions
Digital Health Coaching (Patient-Level Intervention), Practice Facilitation (Clinic-Level Intervention)
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Oct 19, 2026, 2:29 PM EDT
Completed No phase listed Observational

Cardiopulmonary Exercise Tests in Patients With Long COVID

NCT06394921
View directory record Official record
Conditions
Long COVID, COVID Long-Haul
Interventions
2 day cardiopulmonary exercise test
Procedure
Lead sponsor
Sheffield Hallam University
Other
Eligibility
18 Years to 65 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Oct 19, 2026, 2:29 PM EDT
Not yet recruiting No phase listed Observational

Evaluation of a Point-of-care Lateral Flow Assay in Glial Fibrillary Acidic Protein (GFAP) and D-dimer in Diagnosis of Large Vessel Occlusion Acute Ischemic Stroke in a Pediatric Hospital

NCT07474675
View directory record Official record
Conditions
Stroke Code, Large Vessel Occlusion, Acute Ischemic Stroke
Interventions
Point of Care Rapid Assay
Device
Lead sponsor
Boston Children's Hospital
Other
Eligibility
0 Years to 21 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 19, 2026, 2:29 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Clinical Study Using MEDI-551 in Adult Participants With Relapsed or Refractory Advanced B-Cell Malignancies

NCT00983619
View directory record Official record
Conditions
B-cell Malignancies, Cancer
Interventions
MEDI-551, Rituximab
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
13
States / cities
Birmingham, Alabama • La Jolla, California • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated May 13, 2020 · Synced Oct 19, 2026, 2:29 PM EDT
Completed Not applicable Interventional Results available

Crossing the Divide: Piloting Integrated Care to Reduce Amputations Among Rural Patients With Diabetic Foot Ulcers

NCT05203471
View directory record Official record
Conditions
Diabetic Foot, Diabetic Ulcer of Left Foot, Diabetic Ulcer of Right Foot, Amputation
Interventions
integrated care model
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 89 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 19, 2026, 2:29 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Randomized Controlled Trial of the Myndlift BPT App

NCT05182424
View directory record Official record
Conditions
ADHD, Behavioral Disorder
Interventions
Myndlift BPT App & As-Needed Therapist Support
Behavioral
Lead sponsor
New York University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Oct 19, 2026, 2:29 PM EDT
Completed Phase 3 Interventional Results available

An Open-Label Phase 3 Study of BMN 165 for Adults With PKU Not Previously Treated w/ BMN 165

NCT01819727
View directory record Official record
Conditions
Phenylketonuria
Interventions
BMN 165
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
18 Years to 70 Years
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
31
States / cities
La Jolla, California • Oakland, California • Aurora, Colorado + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 19, 2026, 2:29 PM EDT
Not listed Not applicable Interventional

Multispectral Digital Colposcope With Probe for Detection of Cervical Intraepithelial Neoplasia

NCT02406352
View directory record Official record
Conditions
Carcinoma in Situ of Uterine Cervix, Cervical Intraepithelial Neoplasias, High Grade Cervical Intraepithelial Neoplasia
Interventions
Multispectral Digital Colposcope with probe
Device
Lead sponsor
Brookdale University Hospital Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
618 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Apr 10, 2015 · Synced Oct 19, 2026, 2:29 PM EDT
Active, not recruiting Not applicable Interventional

Understanding Quality of Life Among Patients With Cancer Receiving Palliative Care

NCT05331625
View directory record Official record
Conditions
Cancer
Interventions
Offering Additional Resources to Promote Symptom Management
Behavioral
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 19, 2026, 2:29 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHL

NCT02564744
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma, B-cell Non-Hodgkin's Lymphoma
Interventions
Debio 1562, Rituximab
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
9
States / cities
Birmingham, Alabama • Urbana, Illinois • Minneapolis, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2024 · Synced Oct 19, 2026, 2:29 PM EDT
Recruiting Phase 3 Interventional

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

NCT06203210
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Ifinatamab deruxtecan, Topotecan, Amrubicin, Lurbinectedin
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
30
States / cities
Springdale, Arkansas • Fullerton, California • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 19, 2026, 2:29 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Care of Persons With Dementia in Their Environments (COPE) in Programs of All-Inclusive Care of the Elderly (PACE)

NCT04165213
View directory record Official record
Conditions
Frontotemporal Dementia, Dementia, Multi-Infarct Dementia, Vascular Dementia, Mixed Dementia, Alzheimer Disease, Lewy Body Disease, Pick Disease, Neurocognitive Disorders
Interventions
Care of Older Persons in their Environment (COPE) online module training
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years to 100 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced Oct 19, 2026, 2:29 PM EDT
Active, not recruiting Phase 2 Interventional

Ipilimumab and Nivolumab in Recurrent Extensive Stage Small Cell Lung Cancer After Receiving Platinum-based Chemotherapy

NCT03670056
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Combination immunotherapy with Ipilimumab and Nivolumab
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 20, 2025 · Synced Oct 19, 2026, 2:29 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of RAD001 in Participants With Mantle Cell Lymphoma Who Are Refractory or Intolerant to Velcade® Therapy

NCT00702052
View directory record Official record
Conditions
Lymphoma, Mantle- Cell
Interventions
Everolimus
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 90 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
31
States / cities
Multiple Locations, Arizona • Fayetteville, Arkansas • Concord, California + 25 more
Source: ClinicalTrials.gov public record
Updated May 25, 2021 · Synced Oct 19, 2026, 2:29 PM EDT
Completed No phase listed Observational

Study for the Prediction of Active Rejection in Organs Using Donor-derived Cell-free DNA Detection

NCT03984747
View directory record Official record
Conditions
Transplant Rejection, Allograft Rejection, Complications
Interventions
Not listed
Lead sponsor
Natera, Inc.
Industry
Eligibility
2 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
4
States / cities
San Carlos, California • San Diego, California • The Bronx, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Oct 19, 2026, 2:29 PM EDT
Enrolling by invitation No phase listed Observational

A 90 Day Observational Study as an Extension to the Phase 3,Open Labeled Exploratory Study of RELiZORB

NCT05635747
View directory record Official record
Conditions
Short Bowel Syndrome, Malabsorption
Interventions
Relizorb Enzyme Cartridge
Device
Lead sponsor
Boston Children's Hospital
Other
Eligibility
2 Years to 18 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Los Angeles, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 19, 2026, 2:29 PM EDT
Completed No phase listed Observational

Feasibility of an Evidence-based Walking Program in Cancer Pts 60+ During Chemotherapy

NCT01789983
View directory record Official record
Conditions
Breast Cancer, Colon Cancer, Lung Cancer
Interventions
Walk With Ease Program, Collect Blood, GA and Other Survey Tools
Behavioral · Other
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
60 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 20, 2024 · Synced Oct 19, 2026, 2:29 PM EDT
Terminated Not applicable Interventional

Access to EyeGlasses for School-aged Children

NCT05588362
View directory record Official record
Conditions
Myopia, Amblyopia, Hyperopia, Refractive Errors
Interventions
Fitz Frames 3-D Printed Glasses
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
5 Years to 17 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 19, 2026, 2:29 PM EDT
Terminated No phase listed Observational

SCRI Tissue Testing Registry

NCT00965861
View directory record Official record
Conditions
Melanoma, Myelodysplastic Syndrome, Multiple Myeloma, Lymphoma
Interventions
Tissue Registry Study
Other
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 28, 2013 · Synced Oct 19, 2026, 2:29 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer

NCT06800313
View directory record Official record
Conditions
Metastatic Prostate Cancer
Interventions
JNJ-101556143 Formulation 1, JNJ-101556143 Formulation 2, JNJ-101556143 Formulation 3
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
17
States / cities
Colorado Springs, Colorado • Denver, Colorado • New Haven, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 19, 2026, 2:29 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer

NCT05119296
View directory record Official record
Conditions
Thyroid Cancer
Interventions
Pembrolizumab
Drug
Lead sponsor
Saad A Khan
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 19, 2026, 2:29 PM EDT
Terminated Phase 2 Interventional Results available

Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma

NCT01709162
View directory record Official record
Conditions
Melanoma
Interventions
Ipilimumab, Chemotherapy
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
7
States / cities
Birmingham, Alabama • Aurora, Colorado • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2015 · Synced Oct 19, 2026, 2:29 PM EDT
Terminated Phase 1 Interventional Results available

Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma

NCT03267940
View directory record Official record
Conditions
Cholangiocarcinoma Non-resectable, Cholangiocarcinoma, Intrahepatic, Cholangiocarcinoma, Extrahepatic, Gallbladder Adenocarcinoma
Interventions
PEGPH20, CIS, GEM, Atezolizumab
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
26
States / cities
Phoenix, Arizona • Tucson, Arizona • Duarte, California + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2020 · Synced Oct 19, 2026, 2:29 PM EDT
Completed No phase listed Observational

Transforming PCI Informed Consent Into an Evidence-based Decision-making Tool

NCT01383382
View directory record Official record
Conditions
Non-emergent Percutaneous Coronary Intervention (PCI)
Interventions
Not listed
Lead sponsor
Saint Luke's Health System
Other
Eligibility
18 Years and older
Enrollment
1,399 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
7
States / cities
Oakland, California • Springfield, Illinois • Springfield, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2012 · Synced Oct 19, 2026, 2:29 PM EDT